conf 3/10 partial
enthusiasm:21.0 · trend:8 · quantifies:0 · impact:0 · under_radar:14 · credibility:0 · business_impact:4 · disruption:0 · commitment:0 · confirmation:4
Enthusiasm latest 7 / prev 7 (rising)
Solventum’s AI story is almost entirely Health Information Systems / revenue cycle management autonomous medical coding: management treats AI as an enabler, not the moat—rules, compliance rigor, proprietary data, and workflows are. Enthusiasm is substantive but disciplined (opportunity > threat; AI is not sufficient alone), with rising specificity on adoption (50% of customers; 80%–90% of codes eventually autonomous) but no disclosed AI revenue, margin, or bookings attribution. Credibility rests on long tenure in coding, scale datasets, and traction claims in inpatient/outpatient RCM, not on quantified financial impact from AI.
Grounded on actual base — revenue $8.3B · net income $1.6B · net margin 18.7% · diluted EPS 8.88
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: low (model's call-read: high; verdict above is the hard-data one used for ranking) · confidence: 3/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|---|---|---|---|
| 80–90% of all inpatient/outpatient coding eventually fully autonomous other · soft | 80% to 90% of coding | Capability/TAM statement with NO timeframe ('eventually') and NO disclosed revenue base for autonomous coding. The line sits inside HIS (annualized ~$342M×4=$1,368M, ~16.4% of total revenue), but no $/customer, revenue-per-code, pricing uplift or internal cost-save base is given. Customer economics (FTE elimination) accrue client-side per management. Cannot translate a code-automation share into next-FY revenue/EPS without inventing a P&L bridge — declined. | ||
| ~50% of customers move to autonomous coding (strategic plan period) engagement · soft | close to 50% of customers | Penetration/adoption target affecting HIS. HIS annualized ~$1,368M is disclosed, but per-customer autonomous-coding revenue, ACV/take-rate uplift on conversion, customer count and starting penetration are NOT disclosed, and the horizon is the multi-year strategic plan, not next FY. No way to size next-FY incremental revenue from a customer-count percentage without fabricating per-customer economics — declined. Not in aggregate. | ||
| ~1M+ proprietary reimbursement coding rules/algorithms (AI moat) other · soft | close to 1 million plus | Competitive-moat / training-data asset metric (rules count). No revenue, margin or savings figure attached; not P&L-quantifiable without assumed share/pricing effects. | ||
| HIS organic sales +4.7% (Q1 FY2026; AI not broken out) revenue · soft | 4.7% organic on $342M segment sales | Q1 FY26 HIS sales $342M; prior-year Q1 = $342M/1.047 = $326.65M; one-quarter YoY Δ = $15.35M. Annualized at Q1 run rate HIS ≈ 4×$342M = $1,368M; if +4.7% held full year, segment Δ ≈ $64.30M → consolidated rev_uplift_pct ≈ 100×$64.30M/$8,325M = 0.77%. BUT management attributes growth to RCM + performance management broadly, AI NOT broken out → AI-attributable slice unisolable, already in segment-growth consensus. Illustrative-only EPS ceiling @18.69% net margin on consensus NI ≈ $12.0M (~1.1%) — not AI-attributed, excluded from aggregate. | ||
| HIS organic sales +3.2% (Q4 FY2025; AI not broken out) revenue · soft | 3.2% organic on $348M segment sales | Q4 FY25 HIS sales $348M; prior-year Q4 = $348M/1.032 = $337.21M; one-quarter YoY Δ = $10.79M. Annualized HIS ≈ 4×$348M = $1,392M; if +3.2% full year, segment Δ ≈ $44.54M → consolidated rev_uplift_pct ≈ 0.54%. AI not broken out (RCM software + performance management) → not AI-attributable; informs HIS run-rate (~$1.37–1.39B, ~16–17% of total) only. Excluded from AI aggregate. |
Assumptions: Next-FY = FY2026. Solventum is adopter-side (AI improves its OWN HIS software; it does not sell AI compute/chips), so no supplier side. Would-be defaults if a $ anchor existed: 21% tax on opex saves (none quantified); incremental margin at the software/services end (HIS is the software segment, ~$1.37B, ~16.4% of total); EPS sized off consensus ADJUSTED basis (~$1.06–1.15B NI / 175.3M shares, EPS ~$6.03–6.55), NOT the GAAP base ($1,556M / $8.88) which is distorted by one-offs. None applied — no claim carries a next-FY AI dollar anchor. HIS annualized from disclosed quarterly sales ($342M Q1 FY26, $348M Q4 FY25). No bookings/revenue conversion (no bookings $ claims). Customer ramp to ~50% not phased to FY26 absent disclosed starting penetration or $/account uplift.
Top line: Not quantifiable from disclosure. Every AI claim is a capability/adoption/moat metric (80–90% of codes eventually autonomous; ~50% of customers converting over a multi-year plan; ~1M+ proprietary rules) with no attached revenue dollars and, where a horizon exists, it is multi-year not next-FY. The only hard revenue figures (HIS organic +4.7% Q1FY26 / +3.2% Q4FY25, ~$1.37B annualized, ~16% of total, ~$45–64M annualized segment increment = ~0.5–0.8% of consolidated revenue) explicitly do NOT break out AI, so the AI-attributable slice cannot be isolated. Adopter-side aggregate rev uplift = null.
Bottom line: No quantified Solventum opex/FTE or margin expansion from AI. Customer economics (FTE elimination, productivity, better revenue capture) accrue to Solventum's CUSTOMERS, not as Solventum opex savings, so no cost-saving dollar flows to EPS. Denominator caution: consensus adjusted NI (~$1.06–1.15B) sits BELOW GAAP ($1,556M), so any EPS% must be sized off the lower adjusted base — moot, numerator unquantified. Hypothetical non-AI ceiling: all annualized HIS organic growth ($64.3M at 4.7%) at 18.69% margin ≈ $12.0M NI ≈ 1.1% vs consensus — not AI-specific, not in aggregate. Consensus EPS path FY25→FY26→FY27 ≈ $6.03→$6.55→$7.05 (+8.6% then +7.6%); no incremental AI EPS layered on. est_eps_uplift_pct = null.
[impact n/m (all claims soft/unanchored)] Adopter-side aggregate est_rev_uplift_pct and est_eps_uplift_pct are null (no anchored AI $). Consensus revenue is roughly flat-to-down then recovering: FY2025 $8,255M → FY2026 $8,186M (−0.8%; ~$139M / ~1.7% below FY25 actual $8,325M) → FY2027 $8,473M (+3.5%), with EPS growth ~+8.6% then ~+7.6% — modest, margin/deleverage-driven, not an AI inflection. The in-numbers HIS growth (~3–5% on ~16% of revenue ≈ ~0.5–0.8% of total) is consistent with what consensus already carries, so the realized, quantified AI contribution looks priced in. The transformational optionality (80–90% of coding eventually autonomous, ~50% customer conversion) is genuinely NOT in near-term consensus but is unquantified and long-dated, so no math points above consensus. Without a management $ target, cannot show consensus is behind on AI; absence of quantified upside is consistent with AI embedded in the organic HIS narrative rather than modeled as discrete upside.
partial
Near-identical answers: both null all AI uplift pcts, adopter-side, unclear vs consensus, confidence 3. Only priced_in (high vs medium) and a few type labels differed.
| Field | Opus 4.8 | GPT-5.5 |
|---|---|---|
| Rev uplift % | – | – |
| EPS uplift % | – | – |
| Priced in | medium | – |
| vs analysts | unclear | – |
| Confidence | 3 | – |
| Top line | Not quantifiable from disclosure. Every AI claim is a capability/adoption metric (80-90% of codes eventually autonomous; ~50% of customers converting over a multi-year plan; ~1M+ proprietary rules) with no attached revenue dollars and, where a timeframe exists, it is multi-year rather than next-FY. The only hard revenue figures (HIS organic +4.7% Q1FY26 / +3.2% Q4FY25, ~$1.37B annualized, ~16% of total) explicitly do NOT break out AI, so the AI-attributable slice cannot be isolated. Forward statements confirm 'no Solventum P&L figures.' Headline adopter-side uplift = null. | – |
| Bottom line | No bottom-line AI figure is disclosed. Customer economics (FTE elimination, productivity, better revenue capture) are stated as accruing to Solventum's CUSTOMERS, not as Solventum opex savings, so there is no cost-saving dollar to flow to EPS. Note also the denominator caution: consensus net income (~$1.06-1.15B) sits BELOW the GAAP base ($1,556M), so any EPS% would have to be sized off the lower adjusted base — moot here since the numerator is unquantified. est_eps_uplift_pct = null. | – |
| Reasoning | Consensus revenue is essentially flat-to-down then recovering (8,255M→8,186M = -0.8%, →8,473M = +3.5%) with EPS growth of +8.5% then +7.8% — i.e. modest growth driven by post-spin margin/deleverage, not an AI inflection. The in-numbers HIS growth (~3-5% on ~16% of revenue ≈ ~0.5-0.8% of total) is consistent with what consensus already carries, so the realized, quantified AI contribution looks priced in. The big optionality — 80-90% of coding eventually autonomous and ~50% customer conversion — is genuinely NOT in the near-term consensus, but it is also unquantified and long-dated, so there is no math pointing 'above' consensus to call it a clear low-priced-in opportunity. Net: the quantified piece is roughly in the numbers; the transformational piece is unpriced but unsizable. | – |
Rows highlighted where the two models disagreed.
—/100 (no quantified promises) no-quantified-promises 6 calls reviewed
Across Q4 FY2024–Q1 FY2026, Solventum repeatedly promoted AI-driven autonomous coding and RCM momentum but never set a dated numeric AI target (automation rate, revenue, or productivity by year). The only AI figure was a 50%–90% addressable-case automation potential in Q4 FY2024, which lacks a milestone and reads as market sizing, not a deliverable commitment.
Est. revisions falling · Fwd P/E 12.9 · EV/Sales 2.2x
AI claim maps to Product
AI enthusiasm across 6 calls — trend ↗ rising
HIS autonomous coding stayed the sole AI story, deepening from 50-90% potential to Ensemble traction, acceptance metrics, and data-rules differentiation.
6/10 qualitative impact moderate medium-term · soft evidence
Where AI matters: HIS/RCM autonomous medical coding
Autonomous coding is a real, differentiated product vector in ~16% HIS with rising adoption specificity (50% customers, 80-90% codes eventually) and a rules/data moat narrative, but management discloses no AI-attributable revenue or margin and consolidated financial uplift is unquantifiable versus ~84% non-AI Product revenue.
Caveats: No disclosed AI revenue, margin, or bookings—upside remains capability/adoption narrative only; HIS organic growth (~3-5%) is modest and not AI-broken out, so realized upside may already be in segment run-rate; Long-dated 50% customer / 80-90% code autonomy targets lack dated P&L bridges; Generic autonomous-coding competitors could pressure RCM pricing or erode differentiation over time
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 2/10
Solventum monetizes AI-enabled autonomous coding and compliance-heavy RCM software rather than selling billable labor hours; the core ~$6.4B Product franchise is not structurally automated away, and near-term coding disruption favors entrenched proprietary rules/datasets over generic LLM commoditization.
option liquidity: fair
proxy inputs — dollar-ADV $127M · beta 0.655 · px $78.07
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.